U. Vaishampayan

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer.

A. Jimeno, A. Nagrial, D. Rasco, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.

B. Redman, D. Smith, W. Du, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

D. Smith, E. Small, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111).

W. Sakr, D. Petrylak, E. Crawford, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.

P. Philip, A. Shields, T. Bekaii-Saab, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

M. Ahn, D. Rasco, E. Chartash, 2020, Annals of Oncology.

Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma 1

Jeremy T. Wright, A. Kraft, G. Hudes, 2000 .

Neoadjuvant paclitaxel (P), carboplatin (Ca) and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report.

J. Montie, D. Smith, D. Petrylak, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC).

H. Scher, D. Rathkopf, N. Vogelzang, 2009, Journal of Clinical Oncology.

Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.

A. Kraft, J. Wright, G. Hudes, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.